Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary Central Nervous System Lymphoma

Primary central nervous system lymphoma (PCNSL) harbors mutations that reinforce B cell receptor (BCR) signaling. Ibrutinib, a BTK inhibitor, targets BCR signaling and is particularly active in lymphomas with BCR and MYD88 mutations. We performed a proof of concept phase Ib study of ibrutinib monoth...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Cell
Egile Nagusiak: Lionakis, Michail S., Dunleavy, Kieron, Roschewski, Mark, Widemann, Brigitte C., Butman, John A., Schmitz, Roland, Cole, Diane E., Melani, Christopher, Higham, Christine S., Desai, Jigar V., Ceribelli, Michele, Chen, Lu, Thomas, Craig J., Little, Richard F., Gea-Banacloche, Juan, Bhaumik, Sucharita, Stetler-Stevenson, Maryalice, Pittaluga, Stefania, Jaffe, Elaine S., Heiss, John, Lucas, Nicole, Steinberg, Seth M., Staudt, Louis M., Wilson, Wyndham H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5571650/
https://ncbi.nlm.nih.gov/pubmed/28552327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2017.04.012
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak